SL
GILD icon

Summitry LLC’s Gilead Sciences GILD Stock Holding History

Summitry LLC’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Buy
2,104
+217
+11% +$28.6K 0.01% 269
2026
Q1 		$263K Buy
1,887
+39
+2% +$5.46K 0.01% 235
2025
Q4 		$227K Sell
1,848
-1,352
-42% -$164K 0.01% 227
2025
Q3 		$355K Buy
+3,200
New +$364K 0.02% 133

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Summitry LLC's GILD Position: Q2 2026 in Review

Summitry LLC increased its Gilead Sciences (GILD) stake by 11% in Q2 2026, buying an estimated $28.6K and bringing the position to 2,104 shares worth $266K. The position accounts for 0.01% of the portfolio, ranked #269.

Summitry LLC first reported a position in GILD in Q3 2025 and has held it in 4 quarters since. The position peaked at $355K in Q3 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Summitry LLC held 2,104 shares of Gilead Sciences worth $266K as of Q2 2026.
  • Summitry LLC bought 217 Gilead Sciences shares in Q2 2026, an estimated $28.6K.
  • Gilead Sciences made up 0.01% of Summitry LLC's portfolio in Q2 2026, its #269 holding.
  • Summitry LLC first reported a position in Gilead Sciences in Q3 2025 and has held it in 4 quarters since.
  • Summitry LLC's Gilead Sciences position peaked at $355K in Q3 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Summitry LLC's 13F filing for Q2 2026, filed 21 Jul 2026.